It has been customary to view psoriasis as a purely dermatological disease, often ignoring or downplaying its visceral comorbidities. Patients and physicians have also focused on the clearance of skin lesions and the improvement of itching and other self-conscious symptoms. In recent years, as research on psoriasis has intensified, more and more reports of its comorbid visceral diseases have been published. Numerous studies have shown that moderate-to-severe psoriasis has an increased risk of comorbid cardiovascular disease, renal disease, and metabolic syndrome. At the 2012 annual meeting of the Florida Society of Dermatology and Dermatologic Surgery, a scholarly presentation by Jeffrey P. Callen, MD, PhD, chair of the Department of Dermatology at the University of Louisville, noted the high prevalence of undiagnosed or untreated cardiovascular risk factors in patients with moderate-to-severe psoriasis. In total, 59% of patients in this study had at least 2 recognized cardiovascular risk factors and 29% had ≥3 cardiovascular risk factors. Importantly, the investigators found that 19% of patients were all at high risk for cardiovascular events after assessment using the Framingham risk score. says Dr. Callen, “Dermatologists often overlook the impact of skin disease on a patient’s systemic condition, including psoriasis.” Therefore, he recommends a comprehensive comorbidity monitoring program, especially for patients with severe psoriasis. For example, blood pressure, heart rate and body mass index should be checked every 2 years; blood lipids and fasting glucose should be checked every 5 years (or more frequently if other risk factors are also combined); and patients should be asked regularly about problems related to arthritis symptoms. The University of Pennsylvania study also showed that patients with moderate to severe psoriasis are prone to chronic kidney disease. Researchers analyzed data from nearly 144,000 patients with psoriasis aged 19 to 90 years and compared them with nearly 690,000 adults who did not have the disease. The results found that during the seven-year follow-up period, psoriasis patients were more likely than normal to develop chronic kidney disease, with patients with severe psoriasis having a nearly twofold increased risk of developing kidney disease and a more than fourfold increased risk of progressing to kidney failure in the future. Professor Zhang Jianzhong, a well-known dermatologist in China, also pointed out that psoriasis is not just a problem of the epidermis, but an immune-mediated inflammatory disease that is more likely to be accompanied by hypertension, diabetes, hyperlipidemia, cardiovascular disease, arthritis and other diseases than normal people. The above findings indicate that psoriasis does not only affect the skin, but also the internal organs, and that the treatment of psoriasis should not only focus on its skin problems, but more importantly, on whether it has other comorbidities. Here, it is recommended that psoriasis patients and dermatologists should pay great attention to the screening and monitoring of psoriasis cardiovascular, renal, hepatic, endocrine and other visceral comorbidities, so as to understand and detect psoriasis patients’ visceral-related diseases as early as possible, prevent and treat them, and avoid or reduce the occurrence of cardiovascular and other critical and unfavorable events.